Clinical trials
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed/refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 75 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06082102RecruitingPhase 3
Comparing orelabrutinib and lenalidomide with rituximab for MZL
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Bengbu, AuhuiAges 18 years+ - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Birmingham, AlabamaAges 18 years+
Hear when a new Relapsed/Refractory B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed/refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 75 recruiting relapsed/refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed/refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed/refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Relapsed B-Cell Non-Hodgkin Lymphoma
- Refractory Transformed B-cell Non-Hodgkin Lymphoma
- B-Cell Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.